2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution
Open Access
- 1 October 2000
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 11 (10) , 1273-1280
- https://doi.org/10.1023/a:1008368330519
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphomaNuclear Medicine Communications, 1999
- Extranodal malignant lymphoma: detection with FDG PET versus CT.Radiology, 1998
- Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.Radiology, 1997
- The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphomaClinical Oncology, 1996
- FDG-PET for predicting the prognosis of malignant lymphomaAnnals of Nuclear Medicine, 1994
- Staging of lymphoma in adultsClinical Radiology, 1994
- Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.Radiology, 1994
- Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation.Radiology, 1993
- Results of surgical staging in Hodgkin's diseaseBritish Journal of Surgery, 1980
- Staging Laparotomy in Hodgkinʼs DiseaseAnnals of Surgery, 1980